MSD signs Daiichi Sankyo in multibillion dollar deal to develop ADCs
Daiichi Sankyo will receive an upfront payment of $4bn and will be eligible for additional milestone payments of up to $22bn.
Drug Development In NASH
Although metaverse technologies could reinvent healthcare approaches and bring new experiences to healthcare providers and patients, adoption is still at an early stage. There are currently few use cases in the healthcare industry. The metaverse needs to overcome major challenges for healthcare, including regulation and data privacy concerns. Evidence of proven use cases and participation by a critical mass of users are imperative to drive a shift in metaverse investment.
